Perceptive Advisors’s Revolution Medicines RVMD Stock Holding History

Perceptive Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.1M	Buy	+258,600	New	+$26.1M	0.49%	45
2024 Q2	–	Sell	-618,885	Closed	-$19.9M	–	126
2024 Q1	$19.9M	Sell	618,885 -199,997	-24%	-$5.93M	0.35%	62
2023 Q4	$23.5M	Sell	818,882 -502,913	-38%	-$12.1M	0.52%	47
2023 Q3	$36.6M	Buy	+1,321,795	New	+$39.2M	1.22%	26
2022 Q4	–	Sell	-310,500	Closed	-$6.12M	–	108
2022 Q3	$6.12M	Buy	+310,500	New	+$6.82M	0.18%	77
2021 Q1	–	Sell	-224,224	Closed	-$8.88M	–	159
2020 Q4	$8.88M	Hold	224,224	–	–	0.1%	109
2020 Q3	$7.8M	Sell	224,224 -125,776	-36%	-$3.48M	0.11%	98
2020 Q2	$11.1M	Hold	350,000	–	–	0.18%	78
2020 Q1	$7.82M	Buy	+350,000	New	+$9.69M	0.2%	66

Other funds holding RVMD

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors's RVMD Position: Q1 2026 in Review

Perceptive Advisors opened a new position in Revolution Medicines (RVMD) in Q1 2026: 258,600 shares worth $25.1M. The stake represents 0.49% of the portfolio and ranks #45 among its holdings. This is a return to the name: Perceptive Advisors previously reported a position in RVMD as recently as Q1 2024.

Perceptive Advisors first reported a position in RVMD in Q1 2020 and has held it in 9 quarters since. The position peaked at $36.6M in Q3 2023. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

Perceptive Advisors held 258,600 shares of Revolution Medicines worth $25.1M as of Q1 2026.
Revolution Medicines was a new Perceptive Advisors position in Q1 2026.
Revolution Medicines made up 0.49% of Perceptive Advisors's portfolio in Q1 2026, its #45 holding.
Perceptive Advisors first reported a position in Revolution Medicines in Q1 2020 and has held it in 9 quarters since.
Perceptive Advisors's Revolution Medicines position peaked at $36.6M in Q3 2023.
512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.